Peptides DB
Research-centric peptide and protocol reference hub

Erythropoietin (EPO) record · updated 20h ago

Healing & recoveryMetabolic & appetiteGrade A · human clinicalResearch use only
All 26 studiesJump to the evidenceCompare
What is Erythropoietin (EPO) used for?

Erythropoietin (EPO) is a glycoprotein hormone that stimulates red blood cell production in bone marrow, used clinically for anemia and studied in hematology and metabolic research.

How it works: EpoR agonist

Primarily researched for · Healing & recoveryRoute · Subcutaneous injection

Development stage

where Erythropoietin (EPO) sits between preclinical work and regulatory approval
  1. 1Current
    Preclinical
    Animal / in-vitro work
  2. 2Not reached
    Phase 1
    Safety in humans
  3. 3Not reached
    Phase 2
    Efficacy signal
  4. 4Not reached
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 102 registered trials. It describes the research record, not a recommendation.

Identity
NameErythropoietin (EPO)
Chain length—
Molecular weight848 Da
FormulaC42H73NO16
Structure typeNot established
ClassHealing
Research levelExtensively Studied
Discovered byCurated master list · 2026

Mass and formula from PubChem CID 92043599. No verified residue count for this compound.

Pharmacology
MechanismEpoR agonist
RouteSubcutaneous injection
Half-life~4–13 hours
Time to peak~12–24 hours
Duration~1 week
Extraction confidence0.90
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Aug 23, 2026. How this works →
Research stats
Total studies26
Human / animal / cellular14 / 3 / 2
Highest trial phasePreclinical
Years covered2024–2026
Latest study2d ago
Publication history
20242026
Research funding
1,657 NIH projects · $24.5M awarded · through FY2026
Public grants naming this compound. Funding is interest, not evidence.
Safety signals
FAERS reports2
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

26 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
Comparative hematological and serum biochemical profiling of grassland Xichun and Xilingol horses.
FindingRBC count: 9.145 vs 7.905 × 10¹²/L.
Animal2026Full text read0.80
Intravenous iron to treat anaemia before cardiac surgery (ITACS): international, double blind, placebo controlled randomised trial.
TakeawayNot reported in abstract.
Human2026Title only0.10
A Rare Case Report of Polycythemia in a male on Long-Term ART - Think Beyond the common causes.
FindingHemoglobin levels increased to 18.3 g/dL.
Human2026Full text read0.80
Plasma proteome screen of individuals with elevated blood counts to identify diagnostic signatures and biomarkers inherent to patients with myeloproliferative neoplasms
FindingDiagnostic accuracy for identifying PV increased to 99.3% when combined with serum erythropoietin.
Human2026Full text read0.80
Proactive iron supplementation alone in patients on chronic hemodialysis is not sufficient.
FindingHemoglobin rose from 10.07 g/dL ± 1.35 to 10.55 ± 1.70, p=0.0008.
Human2026Full text read0.80
Effects of erythropoietin on cardiac morphometry in exercised male and female adolescent rats.
FindingNot reported in abstract.
Animal2025Full text read0.70
Non-Inferiority of Subcutaneous Efepoetin Alfa Compared to Methoxy Polyethylene Glycol-Epoetin Beta in Stage 3 or 4 CKD Patients: Insights From a Phase 3 Trial.
FindingDifference in response rates was 6.3% with 95% CI -3.1% to 15.5%.
Human2025Full text read0.80
Impact of intravenous iron or exogenous erythropoietin on hemoglobin mass, exercise performance, and acute mountain sickness during altitude acclimatization.
FindingAbsolute Hbmass (g) increased from SL and day 1 to day 13 (P < 0.0001).
Human2025Full text read0.80
Erythropoietin receptor on cDC1s dictates immune tolerance.
TakeawayNot reported in abstract.
—2026Title only0.00
An acetylated Tau-174 CSF biomarker discriminates between TDP-43 and tau pathology in patients with frontotemporal lobar degeneration.
TakeawayNot reported in abstract.
—2026Title only0.10
Casdatifan shows durable response linked to HIF-2α biology in kidney cancer.
TakeawayNot reported in abstract.
—2026Title only0.10
Thrombotic burden and longitudinal outcomes in Thai patients with polycythemia vera.
Finding5-year overall survival was 82.7% (95% CI, 74.61-88.35).
Human2026Full text read0.80

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Erythropoietin (EPO) will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Erythropoietin (EPO) is discussed should be drawn from it.